NCT03421639View on ClinicalTrials.gov

Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Uterine AdenomyosisRecurrent Implantation FailureMenstrual Pain
Interventions
DRUG

GnRH analog (11.25mg Leuprolide acetate)

11.25 Leuprolide acetate only one administration

DRUG

Aromatase inhibitor and GnRH analog

1mg/day of Anastrazole for 3 months

DRUG

Aromatase and GnRH analog (11.25mg Leuprolide acetate)

Leuprolide acetate 11.25mg only one

Trial Locations (3)

Unknown

Spitali Amerikan, Tirana

Nadezda Women's Health Hospital, Sofia

00153

Cerm-Hungaria, Rome

All Listed Sponsors
lead

Centre for Endocrinology and Reproductive Medicine, Italy

NETWORK